Non-Exec Director, Managing Partner, LSP
Joachim Rothe
Joachim (JR) Rothe, PhD, joined EQT Life Sciences (then LSP) in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise.
Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), Binx Health (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), SNIPR Biome (DK) t.Breeders (NASDAQ: Viacell, then NYSE:PKI) and U3 Pharma (D, now: Daiichi-Sankyo).
He was closely involved in many other transactions, like Biomarin, Biovitrum, Omrix and Pharmasset. In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS. Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.